DoseCraft
VapeHeatLabSchedule I
The highest drug classification under US federal law, applied to cannabis, indicating no accepted medical use.
Schedule I is the most restrictive classification under the US Controlled Substances Act of 1970, reserved for substances deemed to have high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision. Cannabis (marijuana) has been classified as Schedule I since the law's passage, alongside heroin and LSD.
Why the Classification Is Controversial
The Schedule I designation of cannabis is widely criticized as scientifically indefensible. The FDA has approved cannabinoid-based medications (Epidiolex, Marinol, Syndros), and 38 states have medical cannabis programs, directly contradicting the no accepted medical use criterion. The DEA has historically used the scheduling to justify severe restrictions on cannabis research, creating a catch-22 where the substance cannot be rescheduled due to insufficient research, but insufficient research exists because the scheduling prevents it.
Current Status
In 2022, President Biden directed the Department of Health and Human Services to review cannabis scheduling. In 2023, HHS recommended rescheduling to Schedule III, and in 2024, the DEA proposed a rule to implement this change. Moving from Schedule I to Schedule III would maintain federal regulation but acknowledge medical value, reduce research barriers, and have significant tax implications for cannabis businesses currently penalized under Section 280E. Full descheduling (removal from the Controlled Substances Act entirely) remains a longer-term goal for many advocates.